Abstract Library

#2173 Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Qiyun T

Authors: Na H, Qiyun T,

Keywords: Exosomes, Serum amyloid A1, Circulating biomarkers, Diagnosis,

#1642 Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: cella c

Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,

Keywords: pancreatic nets, biomarker, everolimus,